Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News enVVeno Medical Corp NVNO

enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system... see more

Recent & Breaking News (NDAQ:NVNO)

enVVeno Medical Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study and Announces Upcoming Investor and KOL Events

Accesswire July 5, 2023

enVVeno Medical Reports First Quarter 2023 Financial Results and Provides Corporate Update

Accesswire May 1, 2023

enVVeno Medical Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

Accesswire March 2, 2023

enVVeno Medical to Present at Cowen's 43rd Annual Health Care Conference

Accesswire February 8, 2023

enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer

Accesswire January 18, 2023

Positive 3-Year VenoValve(R) First-in-Human Data Presented at 49th Annual VEITH Symposium on Vascular and Endovascular Issues

Accesswire November 17, 2022

enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study

Accesswire November 7, 2022

enVVeno Medical Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Accesswire October 27, 2022

enVVeno Medical to Present at the Ladenburg Thalmann 2022 Healthcare Conference

Accesswire September 22, 2022

enVVeno Medical to Host Conference Call and Webcast on September 21, 2022

Accesswire September 19, 2022

enVVeno Medical to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Accesswire September 12, 2022

enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations

Accesswire August 16, 2022

enVVeno Medical Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Accesswire August 3, 2022

enVVeno Medical Announces the Issuance of a New Unique Category III CPT Code Covering the Insertion of a Bioprosthetic Valve into the Femoral Vein

Accesswire July 8, 2022

enVVeno Medical Reports First Quarter 2022 Financial Results and Provides Corporate Update

Accesswire May 2, 2022

enVVeno Medical Announces New U.S. VenoValve(R) Patent

Accesswire April 11, 2022

enVVeno Medical Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update

Accesswire March 28, 2022

One-Year VenoValve(R) Data Published in Peer-Reviewed Journal, Vascular and Endovascular Surgery

Accesswire March 9, 2022

Positive Long-Term VenoValve(R) First-in-Human Data Presented at 34th Annual Meeting of the American Venous Forum

Accesswire February 25, 2022

enVVeno Medical Announces ISO 13485 Certification

Accesswire February 16, 2022